09.09.16
Patheon
3Q Revenues: $482.0 million (+8%)
3Q Earnings: $8.8 million (loss of $21.6 million 3Q15)
YD Revenues: $1.4 billion (+3%)
YTD Loss: $12.4 million (loss of $9.0 million YTD15)
Comments: Drug Product Services (DPS) segment revenue was $309 million in the quarter, up 7% with growth in North America. Pharmaceutical Development Services (PDS) segment revenue was $57 million, up 6% with growth across the network, partially offset by the delay of additional sterile capacity coming online at the company’s Greenville, NC site. Drug Substance Services (DSS) segment revenue was $116 million, up 26% driven by both small and large molecule services, with Biologics accounting for approximately 40% of the segment.
3Q Revenues: $482.0 million (+8%)
3Q Earnings: $8.8 million (loss of $21.6 million 3Q15)
YD Revenues: $1.4 billion (+3%)
YTD Loss: $12.4 million (loss of $9.0 million YTD15)
Comments: Drug Product Services (DPS) segment revenue was $309 million in the quarter, up 7% with growth in North America. Pharmaceutical Development Services (PDS) segment revenue was $57 million, up 6% with growth across the network, partially offset by the delay of additional sterile capacity coming online at the company’s Greenville, NC site. Drug Substance Services (DSS) segment revenue was $116 million, up 26% driven by both small and large molecule services, with Biologics accounting for approximately 40% of the segment.
